Testing dolutegravir dosing in HIV and TB children
Treatments studied
Part of Infections clinical trials.
This study looks at the right way to dose dolutegravir (an HIV medicine) in young children who also have active tuberculosis (TB). Doctors will measure how the medicine moves through the body, especially when standard vs higher-dose rifampicin is used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a child age 4 weeks to under 6 years
- Have HIV infection and be diagnosed with active TB
- Weigh at least 3 kilograms
- Have a parent or legal guardian who can consent
- Recent blood tests must not show serious organ or blood problems (ALT, bilirubin, ANC, platelets, or creatinine)
- No signs of TB meningitis or severe breathing problems right now
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how dolutegravir (an HIV medicine) works in children when taken with weekly rifapentine and isoniazid (medicines to prevent tuberculosis). It may help find the right dose for kids who have HIV and are at risk for TB.
This Phase 2 study tests how well and how safely an HIV medicine (dolutegravir) works when given with rifampicin, a common anti-TB medicine, for people starting HIV treatment during TB treatment. It also studies drug levels in the body to help confirm dosing and safety while treating both infections.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
This study tests a daily combination of two medicines, rifapentine and isoniazid (called 1HP), to prevent tuberculosis (TB) in children under 13 years old. It includes children who have been exposed to TB or are at high risk, both those living with HIV and those without HIV.
This trial compares new HIV medicines to help children and teens who have HIV and are either starting treatment or whose current treatment isn't working. The goal is to find better ways to control the virus and keep kids healthy.
Hear when a new Tuberculosis Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.